GlassScriptPhysician profile
Safwan Malas
NPI 1538194055
$3,453.99
in general payments reported to CMS, 2019-2025
32 companies · $963 in 2025
The $963 reported for 2025 was more than what 82% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $137 · 2021: $103 · 2022: $347 · 2023: $491 · 2024: $861 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,271 · Education: $44.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,270.77 |
| Education | $44.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $495.52 | 2019-2025 | Strensiq |
| Genzyme Corporation | $308.65 | 2023-2025 | |
| Dexcom, INC. | $280.03 | 2021-2025 | Dexcom G6 Transmitter |
| Fresenius Kabi USA, LLC | $227.71 | 2019-2024 | Smoflipid |
| Qol Medical, LLC | $215.31 | 2019-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $207.32 | 2022-2024 | Dupixent |
| Azurity Pharmaceuticals, INC. | $193.11 | 2023-2025 | Triptodur, Triptodur |
| Ascendis Pharma Endocrinology INC | $191.46 | 2023-2025 | Skytrofa |
| Sanofi-Aventis U.S. LLC | $121.95 | 2023-2025 | |
| Alcresta Therapeutics, INC. | $120.68 | 2025 | Relizorb |
| Abbott Laboratories | $100.91 | 2022-2025 | Freestyle Libre 3 |
| Ucb, INC. | $95.74 | 2024-2025 | Fintepla, Briviact |
| Ironwood Pharmaceuticals, INC | $88.39 | 2023 | Linzess |
| 180 Medical, INC. | $87.30 | 2023-2025 | Gentlecath |
| Eton Pharmaceuticals, INC. | $86.70 | 2025 | Nitisinone, Betaine Anhydrous, Carglumic Acid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.06 | 2023-2025 | Eohilia, Gattex |
| Insulet Corporation | $62.43 | 2019-2025 | Omnipod |
| Daiichi Sankyo INC. | $62.06 | 2022-2023 | Injectafer |
| Tandem Diabetes Care, INC. | $58.11 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ipsen Biopharmaceuticals, INC | $56.11 | 2024-2025 | Bylvay |
| Phadia US INC. | $51.37 | 2019-2023 | Immunocap |
| Novo Nordisk INC | $49.01 | 2020-2023 | Sogroya |
| Amphastar Pharmaceuticals, INC. | $43.60 | 2025 | |
| Nestle Healthcare Nutrition INC. | $39.17 | 2022 | |
| Tolmar, INC. | $22.41 | 2025 | Fensolvi |
| Sequel Med Tech, LLC | $21.14 | 2025 | Twiist |
| Biomarin Pharmaceutical INC. | $19.84 | 2023 | Voxzogo 1.2mg |
| Abbvie INC. | $16.84 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.04 | 2023 | Unithroid |
| Mirum Pharmaceuticals, INC. | $13.55 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.16 | 2020 | |
| Travere Therapeutics, INC. | $10.31 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safwan Malas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.